Savant Capital LLC Purchases Shares of 26,347 C4 Therapeutics, Inc. $CCCC

Savant Capital LLC purchased a new stake in C4 Therapeutics, Inc. (NASDAQ:CCCC) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 26,347 shares of the company’s stock, valued at approximately $38,000.

Several other large investors have also made changes to their positions in the business. Crestwood Advisors Group LLC bought a new stake in C4 Therapeutics during the 2nd quarter valued at approximately $41,000. Y Intercept Hong Kong Ltd bought a new stake in shares of C4 Therapeutics in the second quarter valued at approximately $75,000. R Squared Ltd acquired a new stake in shares of C4 Therapeutics in the second quarter worth $44,000. Brookstone Capital Management acquired a new stake in shares of C4 Therapeutics in the second quarter worth $42,000. Finally, Goldman Sachs Group Inc. increased its position in C4 Therapeutics by 8.6% during the first quarter. Goldman Sachs Group Inc. now owns 622,720 shares of the company’s stock worth $996,000 after acquiring an additional 49,065 shares during the period. Institutional investors and hedge funds own 78.81% of the company’s stock.

C4 Therapeutics Stock Performance

Shares of C4 Therapeutics stock opened at $2.44 on Friday. The firm has a market cap of $236.47 million, a P/E ratio of -1.46 and a beta of 2.95. The firm’s 50-day simple moving average is $2.48 and its 200-day simple moving average is $2.13. C4 Therapeutics, Inc. has a twelve month low of $1.09 and a twelve month high of $5.10.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.03. The firm had revenue of $11.23 million during the quarter, compared to analysts’ expectations of $6.28 million. C4 Therapeutics had a negative net margin of 395.51% and a negative return on equity of 64.40%. On average, equities analysts forecast that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on CCCC shares. Wall Street Zen downgraded shares of C4 Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Stephens reiterated an “overweight” rating and issued a $6.00 target price on shares of C4 Therapeutics in a research note on Monday, September 22nd. Barclays lifted their target price on C4 Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Monday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Wednesday, October 8th. Finally, Guggenheim initiated coverage on C4 Therapeutics in a report on Wednesday, September 3rd. They issued a “buy” rating and a $8.00 price target for the company. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, C4 Therapeutics has a consensus rating of “Hold” and a consensus target price of $8.50.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.